LIVE WEBINAR: Saturday, May 22, 2021, 10:15 AM – 4:15 PM Eastern Time

Up for Debate: Oncology Investigators Provide Their Take on Current Controversies in Patient Care – A Daylong Multitumor Educational Webinar in Partnership with Florida Cancer Specialists

A CME-MOC/NCPD Accredited Virtual Event

Register Now

Register for this complimentary event with the “Register Now” button above,
which will take you to our Zoom registration page.

Join us on Saturday, May 22 for this daylong multitumor CME-MOC/NCPD-accredited live webinar
10:15 AM – 4:15 PM Eastern Time

Faculty

Lung Cancer

John V Heymach, MD, PhD
Professor and Chair
Thoracic/Head and Neck Medical Oncology
The University of Texas
MD Anderson Cancer Center
Houston, Texas

Stephen V Liu, MD
Associate Professor of Medicine
Georgetown University Hospital
Washington, DC

Genitourinary Cancers

Maha Hussain, MD, FACP, FASCO
Genevieve Teuton Professor of Medicine
Division of Hematology/Oncology
Deputy Director
Robert H Lurie Comprehensive Cancer Center
Northwestern University Feinberg School of Medicine
Chicago, Illinois

Elizabeth R Plimack, MD, MS
Chief, Division of Genitourinary Medical Oncology
Director, Genitourinary Clinical Research
Professor, Department of Hematology/Oncology
Fox Chase Cancer Center
Temple Health
Philadelphia, Pennsylvania

Chronic Lymphocytic Leukemia and Lymphomas

Jonathan W Friedberg, MD, MMSc
Samuel E Durand Professor of Medicine
Director, James P Wilmot Cancer Institute
University of Rochester
Rochester, New York

Laurie H Sehn, MD, MPH
Chair, Lymphoma Tumour Group
BC Cancer Centre for Lymphoid Cancer
Clinical Professor of Medicine
Division of Medical Oncology
University of British Columbia
Associate Editor, Blood
Vancouver, British Columbia, Canada

Multiple Myeloma

Irene M Ghobrial, MD
Professor of Medicine Lavine Family Chair of Preventative Cancer Therapies Director, Center for Prevention of Progression of Blood Cancers Director, Translational Research in Multiple Myeloma Director, Clinical Investigator Research Program Director, Michele and Steven Kirsch Laboratory Harvard Medical School Dana-Farber Cancer Institute Boston, Massachusetts

Sagar Lonial, MD
Chair and Professor
Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Chief Medical Officer
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

Breast Cancer

Virginia Kaklamani, MD, DSc
Professor of Medicine
Ruth McLean Bowman Bowers Chair in Breast Cancer Research and Treatment
AB Alexander Distinguished Chair in Oncology
Associate Director for Clinical Research
Leader of the Breast Cancer Program
UT Health San Antonio
The University of Texas
MD Anderson Cancer Center
San Antonio, Texas

Nancy U Lin, MD
Associate Professor of Medicine
Harvard Medical School
Associate Chief, Division of Breast Oncology
Director, Metastatic Breast Cancer Program
Dana-Farber Cancer Institute
Boston, Massachusetts

Moderator
Neil Love, MD
Research To Practice
Miami, Florida


CME-MOC/NCPD-accredited LIVE Webinar
Saturday, May 22, 2021
10:15 AM – 4:15 PM Eastern Time

Lung Cancer | 10:15 AM – 11:15 AM ET

Case presentations and topics to be discussed

  • Should the majority of patients with EGFR mutation-positive, Stage IB to IIIA non-small cell lung cancer (NSCLC) receive three years of osimertinib following surgery and adjuvant chemotherapy, if applicable?
  • Should patients with locally advanced EGFR mutation-positive NSCLC be treated with consolidation durvalumab, osimertinib, both or neither after the completion of chemoradiation therapy?
  • Based on the “positive” results from CheckMate-816, is it reasonable to employ nivolumab in combination with chemotherapy as neoadjuvant therapy for patients with resectable NSCLC?
  • Should patients with metastatic NSCLC harboring an EGFR exon 20 mutation at some point in their treatment course be referred for participation in a clinical trial evaluating either mobocertinib or amivantamab?
  • Given the recent FDA approval of lorlatinib as first-line therapy, is that now the preferred treatment approach for patients with newly diagnosed ALK-positive NSCLC?
  • Given its superior intracranial penetration, is entrectinib a better therapeutic option than crizotinib for patients with newly diagnosed ROS1-positive NSCLC?
  • What is the optimal first-line therapy for a patient with newly diagnosed RET-positive NSCLC? For patients with RET-positive disease who will receive targeted therapy are selpercatinib and pralsetinib equally efficacious options?
  • What is the optimal first-line therapy for a patient with newly diagnosed MET exon 14-positive NSCLC? For patients with MET exon 14-positive disease who will receive targeted therapy are capmatinib and tepotinib equally efficacious options?
  • At the current time, should patients with HER2-mutant NSCLC receive trastuzumab deruxtecan at some point in their treatment course? What about patients with HER2-amplified NSCLC?
  • For a patient with newly diagnosed metastatic NSCLC who needs therapy, should clinicians wait until molecular testing results are known before initiating immunotherapy?
  • What is the optimal first-line regimen for a patient with newly diagnosed PD-L1-negative metastatic NSCLC without a targetable tumor mutation?
  • What is the optimal first-line regimen for a patient with newly diagnosed metastatic NSCLC without a targetable tumor mutation with a PD-L1 TPS of 60%?
  • What is the optimal second-line therapy for a patient with metastatic NSCLC who progresses on an immune checkpoint inhibitor-based regimen?
  • What is the optimal first-line treatment for a patient with newly diagnosed extensive-stage small cell lung cancer (SCLC)? Are carboplatin/etoposide/atezolizumab and platinum/ etoposide/durvalumab equally efficacious therapeutic options?
  • What is the optimal second-line treatment for a patient with extensive-stage SCLC who progresses on a front-line anti-PD-L1/chemotherapy combination?
  • What is the optimal first-line treatment for a patient with newly diagnosed unresectable malignant pleural mesothelioma and epithelioid tumor histology? What about for a patient with non-epithelioid histology?

PROGRAM BREAK | 11:15 AM – 11:30 AM ET

Genitourinary Cancers | 11:30 AM – 12:30 PM ET

Case presentations and topics to be discussed

  • What is the optimal first-line therapy for a patient with favorable-risk advanced renal cell carcinoma (RCC)?
  • What is the optimal first-line therapy for a patient with intermediate- or high-risk advanced RCC?
  • Based on available clinical trial data are pembrolizumab/axitinib, cabozantinib/nivolumab and lenvatinib/pembrolizumab essentially equivalent options as first-line therapy for advanced RCC?
  • Is there an optimal second-line treatment for patients with metastatic RCC who progress on a checkpoint inhibitor-based therapy, or should the approach be tailored based on the specific regimen the patient received up front?
  • Given its recent FDA approval, where in the treatment sequence should tivozanib be integrated?
  • Should all patients with advanced prostate cancer undergo genetic testing?
  • What type of diagnostic imaging should clinicians employ in patients with a rising PSA on androgen deprivation therapy in an effort to optimally detect metastatic disease?
  • What is the optimal therapeutic approach for a patient with non-metastatic prostate cancer with a rising PSA on androgen deprivation therapy and a PSA doubling time of 10 months?
  • What is the optimal therapeutic approach for a patient with low-volume hormone-sensitive metastatic prostate cancer?
  • What is the optimal therapeutic approach for a patient with high-volume hormone-sensitive metastatic prostate cancer?
  • Given the recent findings from the ACIS trial, should apalutamide in combination with abiraterone be the preferred treatment choice for a patient with newly diagnosed castration- resistant metastatic prostate cancer without an actionable mutation?
  • What is the optimal therapeutic approach for a patient with newly diagnosed castration- resistant metastatic prostate cancer and a germline BRCA mutation?
  • Which homologous recombination repair abnormalities beyond germline BRCA1/2 warrant treatment with a PARP inhibitor in prostate cancer?
  • What is the optimal therapeutic approach for a patient with castration-resistant metastatic prostate cancer who has previously received docetaxel and has progressed 18 months after beginning abiraterone?
  • Given the recent announcement of positive findings from the Phase III VISION trial, do you believe 177Lu-PSMA-617 will gain FDA approval in the very near future and, if so, do you envision utilizing it versus other evidence-based options?
  • What is the optimal therapeutic approach for a patient with BCG-unresponsive non-muscle-invasive urothelial bladder cancer (UBC)?
  • Based on the results of CheckMate 274, at the current time is it reasonable to offer adjuvant nivolumab to a patient with muscle-invasive bladder cancer and a high risk of recurrence following neoadjuvant chemotherapy and cystectomy?
  • What is the optimal therapeutic approach for a patient with relapsed/refractory UBC and an FGFR gene alteration who has progressed following cisplatin-based chemotherapy followed by avelumab maintenance?
  • How frequently should ophthalmologic evaluations be undertaken for a patient receiving enfortumab vedotin? What about erdafitinib? Should these always be conducted by an ophthalmologist?
  • Can enfortumab vedotin be safely administer to patients with Type II diabetes? Is there a baseline Hgb A1C level beyond which you would not consider it?

PROGRAM BREAK | 12:30 PM – 12:45 PM ET

Chronic Lymphocytic Leukemia and Lymphomas | 12:45 PM – 1:45 PM ET

Case presentations and topics to be discussed

  • What is the optimal first-line therapy for a younger patient with newly diagnosed IGHV- mutated chronic lymphocytic leukemia (CLL)? Does your approach change if the patient has unmutated disease?
  • What is the optimal first-line therapy for an older patient with newly diagnosed IGHV-mutated CLL? Does your approach change if the patient has unmutated disease?
  • What is the optimal first-line therapy for a younger patient with newly diagnosed IGHV- mutated CLL with del(17p)?
  • What is the optimal first-line therapy for an older patient with newly diagnosed IGHV-mutated CLL and a history of atrial fibrillation requiring anticoagulation?
  • Should community-based medical oncologists/hematologists be ordering minimal residual disease (MRD) assessment in any CLL clinical situations? If a CLL patient receiving up-front therapy with venetoclax-obinutuzumab is found to have detectable MRD after one year should treatment be stopped?
  • Should patients with CLL progressing on both a BTK and Bcl-2 inhibitor be referred for participation in a clinical trial evaluating a non-covalent BTK inhibitor over other available therapeutic and protocol options?
  • Do you believe community-based oncologists/hematologists should be presenting the R2 regimen of lenalidomide/rituximab as a front-line option to patients with newly diagnosed follicular lymphoma (FL)?
  • Given the recent FDA approval of axicabtagene ciloleucel, should all patients with relapsed/ refractory R/R FL be counseled about the risks and benefits of this therapeutic approach?
  • What is the optimal therapeutic approach for a patient with FL and an EZH2 mutation who has progressed on bendamustine/rituximab and then lenalidomide/rituximab?
  • Do you believe that there are discernable differences in terms of efficacy or tolerability that make one of the four FDA-approved PI3 kinase inhibitors for R/R FL a better therapeutic option?
  • For a patient with R/R diffuse large B-cell lymphoma (DLBCL) do you believe there is an optimal approach to the therapeutic sequencing of polatuzumab vedotin, tafasitamab/lenalid- omide, selinexor and CAR T-cell therapy?
  • Do you view the three available CD19-directed CAR T-cell therapies as equivalent therapeutic options, or are there distinct differences between these agents that would lead you to refer patients for one versus the other?
  • Is it reasonable to treat a patient who has progressed following CD19-directed CAR T-cell therapy with tafasitamab/lenalidomide and vice versa?
  • Do you believe that there are discernable differences in terms of efficacy or tolerability that make one of the three FDA-approved BTK inhibitors for mantle cell lymphoma (MCL) a better therapeutic option?
  • Where in the treatment sequence is the appropriate time to refer a patient with R/R MCL for CAR T-cell therapy?
  • For which patients with newly diagnosed advanced-stage Hodgkin lymphoma (HL) do you recommend brentuximab vedotin in combination with AVD as first-line therapy and which ones do you believe can be treated with some other approach?
  • What is the optimal first-line therapy for an older patient with newly diagnosed advanced- stage HL?
  • Is it reasonable to treat a patient with BV in combination with an anti-PD-1 antibody in any HL clinical situation outside of a clinical trial?

PROGRAM BREAK | 1:45 PM – 2:00 PM ET

Multiple Myeloma | 2:00 PM – 3:00 PM ET

Case presentations and topics to be discussed

  • What is the optimal first-line and maintenance therapy for a transplant-eligible patient with newly diagnosed average-risk multiple myeloma (MM)?
  • What is the optimal first-line and maintenance therapy for a transplant-eligible patient with newly diagnosed high-risk (eg, del[17p]) MM?
  • What is the optimal first-line and maintenance therapy for a transplant-ineligible patient with newly diagnosed average-risk MM?
  • What is the optimal first-line and maintenance therapy for a transplant-ineligible patient with newly diagnosed high-risk ((eg, del[17p]) MM?
  • For a patient whom you elect to treat with front-line RVd-daratumumab, how do you approach maintenance therapy?
  • Should community-based medical oncologists/hematologists be ordering minimal residual disease (MRD) assessment in any MM clinical situations? If a physician elects to order MRD testing for an MM patient, is there an optimal methodology for doing so?
  • Given its upcoming PDUFA date, do you believe idecabtagene vicleucel (ide-cel) will be endorsed by the FDA? If yes, for which types of patients with relapsed/refractory (R/R) MM will you recommend this therapy?
  • If ide-cel is approved, where in the treatment sequence do you envision utilizing it opposite other evidence-based options?
  • Is it reasonable to utilize BCMA-directed CAR T-cell therapy in a patient who has previously received belantamab mafodotin and vice versa?
  • In the R/R setting do you consider daratumumab and isatuximab to be essentially equivalent therapeutic options (when combined with the same agents)?
  • Is it reasonable to employ isatuximab for a patient who has previously progressed on daratumumab?
  • Where in the treatment sequence are you typically incorporating selinexor, and is it best utilized solely with dexamethasone or as part of a triplet regimen?
  • What is the optimal dose and schedule of selinexor?
  • When in the treatment course is the optimal time to recommend belantamab mafodotin?
  • How frequently should ophthalmologic evaluations be undertaken for a patient receiving belantamab mafodotin? Should these always be conducted by an ophthalmologist?
  • Given its recent FDA approval, where in the treatment sequence are you planning to integrate melflufen?
  • Is it reasonable to employ venetoclax for a patient with R/R t(11;14) MM? If yes, would you use it solely with dexamethasone or as part of a triplet regimen?
  • What is the optimal dose and schedule of venetoclax in MM, and is tumor lysis syndrome prophylaxis necessary?
  • Should community-based medical oncologists/hematologists be attempting to measure Bcl-2 expression in patients with MM?

PROGRAM BREAK | 3:00 PM – 3:15 PM ET

Breast Cancer | 3:15 PM – 4:15 PM ET

Case presentations and topics to be discussed

  • Should all patients with localized breast cancer (BC) undergo genetic testing?
  • If a patient with localized BC is found to have a germline BRCA1/2 mutation, should she be offered treatment with adjuvant olaparib?
  • Should all patients with ER-positive, HER2-negative localized BC and 1-3 positive lymph nodes have their tumors assessed via the 21-gene assay?
  • Which patients, if any, with ER-positive, HER2-negative localized BC, 1-3 positive lymph nodes and a Recurrence Score of 25 or lower should be offered adjuvant chemotherapy?
  • Which patients, if any, with high-risk ER-positive, HER2-negative localized BC should be offered treatment with adjuvant abemaciclib?
  • Which patients, if any, with HER2-positive localized BC should be offered one year of extended adjuvant therapy with neratinib?
  • At the current time, is it reasonable to utilize an anti-PD-1/PD-L1 antibody plus chemotherapy as neoadjuvant therapy for patients with triple-negative breast cancer (TNBC)?
  • What is the optimal first-line therapy for patients with metastatic PD-L1-positive TNBC? Does the specific chemoimmunotherapy regimen matter?
  • What is the optimal first-line therapy for a patient with newly diagnosed PD-L1-negative, BRCA-positive metastatic TNBC (mTNBC)?
  • Given its unique mechanism of action and recent FDA approval, in general should patients with mTNBC receive sacituzumab govitecan after relapse on first-line treatment?
  • What is the optimal therapeutic approach for a patient with HER2-positive metastatic BC (mBC) without brain metastases who progresses on docetaxel/trastuzumab/pertuzumab and then T-DM1?
  • What is the optimal therapeutic approach for a patient with HER2-positive mBC with brain metastases who progresses on docetaxel/trastuzumab/pertuzumab and then T-DM1?
  • Is it reasonable to combine neratinib with other chemotherapeutic agents beyond cape- citabine for patients with metastatic HER2-positive disease?
  • Should the majority of patients with newly diagnosed ER-positive mBC or those who progress on adjuvant endocrine therapy receive a CDK4/6 inhibitor in addition to hormonal therapy as first-line treatment?
  • Should patients who progress on a CDK4/6 inhibitor in combination with endocrine therapy have their tumors tested via next-generation sequencing and be offered alpelisib if PIK3CA mutated?

PROGRAM ADJOURNS | 4:15 PM ET

Target Audience
This live activity has been designed to meet the educational needs of medical oncologists, hematologists, hematology-oncology fellows, nurse practitioners, clinical nurse specialists and other allied cancer professionals involved in the treatment of cancer.

Learning Objectives

LUNG CANCER

  • Evaluate available and emerging data documenting the efficacy and safety of anti-PD-1/PD-L1 antibody-based approaches as neoadjuvant or adjuvant therapy in patients with non-metastatic non-small cell lung cancer (NSCLC).
  • Appraise the FDA approval of anti-PD-L1 antibody consolidation therapy for patients with unresectable Stage III NSCLC who have not experienced disease progression after standard platinum- based chemotherapy concurrent with radiation therapy, and appropriately integrate this strategy into routine clinical practice.
  • Acknowledge the FDA approval of adjuvant osimertinib for patients with early-stage NSCLC with an EGFR mutation, and identify individuals for whom treatment with this novel approach would be appropriate.
  • Review published research data documenting the safety and efficacy of EGFR tyrosine kinase inhibitors alone or in combination with other systemic approaches for metastatic NSCLC with an EGFR tumor mutation, and apply this information in the care of appropriately selected individuals.
  • Assess the efficacy and safety of commercially available ALK inhibitors for patients with metastatic NSCLC with an ALK rearrangement, and apply this understanding to select and sequence these drugs as first- and later-line therapy.
  • Recollect other oncogenic pathways (ie, ROS1, RET, MET, HER2) mediating the pathogenesis of tumors in unique patient subsets, and recall published and emerging data with commercially available and experimental agents exploiting these targets.
  • Review recent therapeutic advances related to the use of anti-PD-1/PD-L1 antibodies as monotherapy or in combination with chemotherapy or chemobiologic therapy for metastatic NSCLC, and discern how these approaches can be optimally employed in the management of this disease.
  • Recognize the recent FDA approvals of nivolumab in combination with ipilimumab with and without chemotherapy as first-line treatment for patients with metastatic NSCLC, and appropriately incorporate these novel regimens into current treatment algorithms.
  • Appreciate available clinical trial findings informing the use of immune checkpoint inhibitors in combination with platinum-based chemotherapy for patients with previously untreated extensive-stage small cell lung cancer (SCLC).
  • Design an optimal approach to the clinical care of patients with progressive SCLC, considering the implications of prior therapeutic exposure, symptomatology and other relevant factors.
  • Analyze the biologic basis for the investigation of immune checkpoint inhibitors in patients with malignant pleural mesothelioma and consider the current clinical role of nivolumab in combination with ipilimumab for individuals with previously untreated disease

GENITOURINARY CANCERS

  • Evaluate the published research database supporting the FDA approvals of secondary hormonal agents in the management of nonmetastatic castration-resistant prostate cancer (CRPC), and apply this information in the recommendation of nonresearch treatment options for patients.
  • Explore available data with cytotoxic and secondary hormonal therapy for metastatic hormone-sensitive prostate cancer to design effective treatment plans for patients.
  • Apply clinical research findings in the determination of best-practice selection and sequencing of available treatment modalities for patients with metastatic CRPC.
  • Evaluate the recent FDA approvals of olaparib and rucaparib for patients with metastatic CRPC, and optimally incorporate these agents into clinical management algorithms.
  • Consider published and emerging research information, clinical investigator perspectives and available guideline recommendations to individualize first-line therapy for patients with advanced renal cell carcinoma (RCC).
  • Develop a rational approach to the sequencing of systemic therapies for patients with advanced RCC who experience disease progression on first-line treatment, incorporating multikinase inhibitors, mTOR inhibitors and immunotherapeutic agents.
  • Recognize available clinical trial evidence with immune checkpoint inhibitors for nonmetastatic urothelial bladder carcinoma (UBC) to determine the current and potential utility of this strategy in clinical practice.
  • Review available clinical trial data with anti-PD-1/PD-L1 antibodies for patients with newly diagnosed or relapsed/refractory metastatic UBC in order to optimally incorporate these agents into management algorithms.
  • Recall the mechanisms of action of and pivotal clinical trial findings with enfortumab vedotin and erdafitinib for previously treated locally advanced or metastatic UBC, and identify patients for whom treatment with these novel compounds would be appropriate.
  • Appraise available research data and ongoing clinical trials evaluating novel agents and strategies for prostate cancer, RCC and UBC, and counsel appropriately selected patients about participation in active research protocols.

CHRONIC LYMPHOCYTIC LEUKEMIA AND LYMPHOMAS

  • Individualize the selection and sequencing of systemic therapy for patients with newly diagnosed or relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL), considering clinical presentation, age, performance status (PS), biomarker profile and coexisting medical conditions.
  • Understand published research data informing the selection, sequencing or combining of available therapeutic agents in the nonresearch care of patients with previously untreated or R/R follicular lymphoma (FL).
  • Recognize the mechanisms of action, efficacy and safety of approved and investigational agents for the treatment of diffuse large B-cell lymphoma (DLBCL) to determine the current and potential utility of those agents in clinical practice.
  • Consider patient age, PS and other clinical and biologic factors in the up-front and subsequent treatment of mantle cell lymphoma (MCL).
  • Incorporate available and emerging therapeutic strategies into the best-practice management of newly diagnosed and R/R Hodgkin lymphoma (HL).
  • Assess available clinical trial findings informing the utilization of CD19-directed CAR T-cell therapy for patients with R/R DLBCL, MCL and FL, and counsel appropriately selected individuals regarding the potential benefits of this therapeutic strategy.
  • Implement a plan of care to recognize and manage side effects and toxicities associated with existing and recently approved systemic therapies for CLL, FL, MCL, DLBCL and HL to support quality of life and continuation of treatment.
  • Recall new data with agents and strategies currently under investigation for CLL and various lymphoma subtypes, and discuss ongoing trial opportunities with eligible patients.

MULTIPLE MYELOMA

  • Customize the use of induction, consolidation and maintenance therapeutic approaches for multiple myeloma (MM) in the transplant and nontransplant settings, considering patient- and disease-related factors, including cytogenetic profile.
  • Appreciate clinical trial data informing the front-line use of monoclonal antibody therapy directed at CD38 for patients with MM eligible or ineligible for stem cell transplant, and effectively identify when and how this strategy should be integrated into clinical management.
  • Recognize published research data validating the use of minimal residual disease (MRD) status as a mechanism to predict long-term outcomes with therapy, and use this information to determine the potential role of MRD assays in the management of MM.
  • Consider published research findings and other clinical factors in the best-practice selection, sequencing and combining of established regimens in the care of patients with relapsed/refractory MM.
  • Develop an understanding of the mechanisms of action of and pivotal clinical trial findings with recently FDA-approved novel therapies (eg, isatuximab, selinexor, belantamab mafodotin, melflufen) to facilitate their integration into MM management algorithms.
  • Appreciate available data documenting the activity of chimeric antigen receptor T-cell therapy targeting BCMA in MM, and use this knowledge to identify patients who may be appropriate for a clinical trial of this approach.
  • Recall the design of ongoing clinical trials evaluating novel agents and strategies for MM, and counsel appropriate patients about availability and participation.

BREAST CANCER

  • Analyze published research data to guide the selection and duration of neoadjuvant, adjuvant and extended adjuvant therapy for patients with HER2-overexpressing localized breast cancer (BC).
  • Implement a long-term clinical plan for the management of metastatic HER2-positive BC, incorporating existing and recently approved anti-HER2 therapies.
  • Evaluate the results of genomic assays and other patient- and treatment-related factors to personalize the use of adjuvant systemic therapy for newly diagnosed ER-positive BC.
  • Consider available and emerging clinical trial findings with CDK4/6 inhibitors for localized ER-positive, HER2-negative BC, and assess the potential role of these agents as neoadjuvant or adjuvant treatment.
  • Individualize the selection and sequence of systemic therapy for patients with ER-positive metastatic BC, considering age, menopausal status, prior treatment, PIK3CA mutation status, comorbidities, symptomatology and extent and sites of disease.
  • Review published research data supporting the benefit of chemotherapy in combination with anti- PD-1/PD-L1 antibodies for patients with newly diagnosed PD-L1-positive metastatic triple-negative BC (TNBC), and use this information to make appropriate treatment recommendations.
  • Recall available research data and ongoing clinical trials evaluating anti-PD-1/PD-L1 antibodies for localized TNBC, and determine the current and potential role of these strategies in clinical practice.
  • Assess potential biomarkers of response to PARP inhibition, and use this information to optimize the selection of available genetic testing platforms and related therapeutic interventions for patients with metastatic BC.
  • Recognize emerging Phase III clinical trial findings documenting the efficacy of adjuvant olaparib in patients with high-risk HER2-negative early breast cancer with a BRCA mutation in preparation for the potential availability of this therapeutic strategy.
  • Appraise recent FDA approvals of and ongoing clinical research studies evaluating novel agents and treatment strategies for various forms of BC, and counsel patients about research and nonresearch treatment opportunities.

Accreditation Statements
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Research To Practice is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC).

CME Credit Designation Statement
Research To Practice designates this live activity for a maximum of 5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME and ABIM MOC credit form links will be emailed to each participant within 5 business days of the activity.

NCPD Credit Designation Statements
This educational activity for 5 contact hours is provided by Research To Practice.

This activity is awarded 5 ANCC pharmacotherapeutic contact hours.

To obtain a certificate of completion and receive credit for this event, nurses must return a completed Educational Assessment and Credit Form for the modules they attend. The credit form links will be emailed to participants within 5 business days of the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 5 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialties: medical oncology and hematology.

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information. For those clinicians wishing to receive ABIM MOC credit for attending, you will receive an email after the event with instructions.

Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information
This activity will be submitted to the ONCC for ILNA verification.

Unlabeled/Unapproved Uses Notice
There is no implied or real endorsement of any product by Research To Practice, ACCME or the ANCC. Any off-label use as declared by the FDA will be identified.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME/NCPD activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

Dr FriedbergData and Safety Monitoring Board/Committee: Acerta Pharma — A member of the AstraZeneca Group, Bayer HealthCare Pharmaceuticals, Novartis. Dr GhobrialAdvisory Committee: Aptitude Health, GlaxoSmithKline, GNS Healthcare; Consulting Agreements and Speaker Bureau: AbbVie Inc, Adaptive Biotechnologies Corporation, Aptitude Health, Bristol-Myers Squibb Company, Cellectar Biosciences Inc, Curio Science, Genentech, a member of the Roche Group, GlaxoSmithKline, GNS Healthcare, Janssen Biotech Inc, Karyopharm Therapeutics, Oncopeptides, Sanofi Genzyme, Takeda Oncology. Dr HeymachAdvisory Committee and Consulting Agreements: AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, BrightPath Biotherapeutics Co Ltd, Bristol-Myers Squibb Company, Catalyst Pharmaceuticals, EMD Serono Inc, Foundation Medicine, Genentech, a member of the Roche Group, GlaxoSmithKline, Guardant Health, Hengrui Therapeutics Inc, Janssen Biotech Inc, Kairos Venture Investments LLC, Leads Biolabs, Lilly, Mirati Therapeutics, Nexus Health Systems, Novartis, Pneuma Respiratory, Roche Laboratories Inc, Sanofi Genzyme, Spectrum Pharmaceuticals Inc, Takeda Oncology; Contracted Research: AstraZeneca Pharmaceuticals LP, GlaxoSmithKline, Spectrum Pharmaceuticals Inc; Licensing and Fees: Spectrum Pharmaceuticals Inc. Dr HussainAdvisory Committee: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Janssen Biotech Inc, Pfizer Inc; Contracted Research (to Institution): Arvinas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Genentech, a member of the Roche Group, Pfizer Inc, The Prostate Cancer Clinical Trials Consortium; Honoraria: Astellas, AstraZeneca Pharmaceuticals LP, Phillips Gilmore Oncology Communications Inc, Precisca, Sanofi Genzyme. Dr KaklamaniConsulting Agreements: Amgen Inc, AstraZeneca Pharmaceuticals LP, Athenex, Celldex Therapeutics, Eisai Inc, Immunomedics Inc, Puma Biotechnology Inc; Data and Safety Monitoring Board/Committee: Sanofi Genzyme; Speakers Bureau: AstraZeneca Pharmaceuticals LP, Celgene Corporation, Daiichi Sankyo Inc, Eisai Inc, Exact Sciences Inc, Genentech, a member of the Roche Group, Novartis, Pfizer Inc, Puma Biotechnology Inc, Seagen Inc. Dr LinConsulting Agreements: Aleta Biotherapeutics, AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Denali Therapeutics, Novartis, Nuvation Bio, Olema Oncology, Pfizer Inc, Prelude Therapeutics, Seagen Inc, Suzhou Zanrong Pharmaceutical Technology Co Ltd; Contracted Research: Array BioPharma Inc, a subsidiary of Pfizer Inc, AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, Merck, Novartis, Pfizer Inc, Seagen Inc, Suzhou Zanrong Pharmaceutical Technology Co Ltd. Dr LiuAdvisory Committee: AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Blueprint Medicines, Bristol-Myers Squibb Company, Daiichi Sankyo Inc, G1 Therapeutics, Genentech, a member of the Roche Group, Guardant Health, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Lilly, PharmaMar, Regeneron Pharmaceuticals Inc, Takeda Oncology; Consulting Agreements: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Inivata, Janssen Biotech Inc, Lilly, Merck, Merck Sharp & Dohme Corp, Pfizer Inc; Contracted Research: Alkermes, Bayer HealthCare Pharmaceuticals, Blueprint Medicines, Bristol-Myers Squibb Company, Corvus Pharmaceuticals, Debiopharm Group, Elevation Oncology, Genentech, a member of the Roche Group, Lilly, Merck, Merus BV, Pfizer Inc, Rain Therapeutics, RAPT Therapeutics, Turning Point Therapeutics; Data and Safety Monitoring Board/Committee: Advantagene Inc, Candel Therapeutics. Dr LonialConsulting Agreements: Amgen Inc, Bristol-Myers Squibb Company, Celgene Corporation, GlaxoSmithKline, Janssen Biotech Inc, Novartis, Takeda Oncology; Contracted Research: Celgene Corporation, Janssen Biotech Inc, Takeda Oncology. Dr PlimackAdvisory Committee: Bristol-Myers Squibb Company, Calithera Biosciences, Genentech, a member of the Roche Group, Janssen Biotech Inc, MEI Pharma Inc, Merck, Pfizer Inc, Seagen Inc; Contracted Research: Astellas, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Merck; Data and Safety Monitoring Board/Committee: AstraZeneca Pharmaceuticals LP, Infinity Pharmaceuticals Inc, Pfizer Inc. Dr SehnAdvisory Committee and Consulting Agreements: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Amgen Inc, Apobiologix, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Celgene Corporation, Genentech, a member of the Roche Group, Gilead Sciences Inc, Incyte Corporation, Janssen Biotech Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lundbeck, Merck, MorphoSys, Novartis, Pfizer Inc, Roche Laboratories Inc, Sandoz Inc, a Novartis Division, Seagen Inc, Takeda Oncology, Teva Oncology, Verastem Inc; Contracted Research: Teva Oncology.

MODERATORDr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Eisai Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Turning Point Therapeutics Inc and Verastem Inc.

Research To Practice CME/NCPD Planning Committee Members, Staff and Reviewers — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.